Login / Signup

A phase I dose escalation, dose expansion and pharmacokinetic trial of gemcitabine and alisertib in advanced solid tumors and pancreatic cancer.

Justin A ChenJasmine C HuynhChun-Yi WuAi-Ming YuKaren MatsukumaThomas J SemradDavid R GandaraTianhong LiJonathan W RiessKit TamPhilip C MackAnthony MartinezNichole MahaffeyKaren L KellyEdward J Kim
Published in: Cancer chemotherapy and pharmacology (2022)
This trial established the recommended phase 2 dose of alisertib 50 mg to be combined with gemcitabine. Gemcitabine and alisertib are a feasible strategy with potential for disease control in multiple heavily pre-treated tumors, though gastrointestinal and hematologic toxicity was apparent.
Keyphrases